Eco-friendly materials for next-generation vaccination: From concept to clinical reality

Abstract

The vaccine is a premier healthcare intervention strategy in the battle against infectious infections. However, the development and production of vaccines present challenges in terms of complexity, cost, and time consumption. Alternative methodologies, such as nonthermal plasma and plant-based technologies, have emerged as potential alternatives for conventional vaccine manufacturing processes. While plasma-based approaches offer a rapid and efficient pathogen inactivation method devoid of harsh reagents, plant-based techniques present a more economically viable and scalable avenue for vaccine production. The imperative urges these approaches to address pressing global health challenges posed by emerging and recurring infectious diseases, surpassing the limitations of traditional vaccine fabrication methods. The primary goal of this review is to provide a comprehensive overview of the current research landscape, covering conceptualization, production, and potential advantages of plasma-based and plant-based vaccines. Furthermore, exploring the obstacles and opportunities intrinsic to these strategies is undertaken, elucidating their potential impact on vaccination strategies. This systematic presentation specifies a detailed outline of recent vaccine research and developments, emphasizing the possibility of advanced green approaches to produce effective and secure vaccination programs.

Keywords

cold plasma / environment-friendly / green methods / immunization / plant-based vaccine

References

[1] Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: current progress and future challenges. Chem Rev. 2019; 120: 3210-3229.

[2] Ye T, Zhong Z, García-Sastre A, Schotsaert M, De Geest BG. Current status of COVID-19 (pre)clinical vaccine development. Angew Chem Int Ed. 2020; 59: 18885-18897.

[3] Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc, B. 2014; 369: 20130433.

[4] Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2020; 21: 83-100.

[5] Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022; 12: 015477.

[6] Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020; 12: 254.

[7] Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011; 3: 73-78.

[8] Rabdano SO, Ruzanova EA, Pletyukhina IV, et al. Immunogenicity and in vivo protective effects of recombinant nucleocapsid-based SARS-CoV-2 Vaccine Convacell®. Vaccines. 2023; 11: 874.

[9] Lu J, Lu G, Tan S, et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020; 30: 936-939.

[10] Nicholson LB. The immune system. Essays Biochem. 2016; 60: 275-301.

[11] Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014; 371: 918-931.

[12] Wilkins AL, Kazmin D, Napolitani G, et al. AS03-and MF59-adjuvanted influenza vaccines in children. Front Immunol. 2017; 8: 1760.

[13] Wang G, Zhu R, Yang L, et al. Non-thermal plasma for inactivated-vaccine preparation. Vaccine. 2016; 34: 1126-1132.

[14] Mohamed H, Esposito RA, Kutzler MA, Wigdahl B, Krebs FC, Miller V. Nonthermal plasma as part of a novel strategy for vaccination. Plasma Process Polym. 2020; 17: 2000051.

[15] El Jaddaoui I, Al Idrissi N, Hamdi S, et al. Plant-based vaccines against COVID-19 for massive vaccination in Africa. Front Drug Des Discov. 2022; 2: 909958.

[16] Aboul-Ata EA-A, Vitti A, Nuzzaci M, et al. Plant-based vaccines: novel and low-cost possible route for Mediterranean innovative vaccination strategies. Adv Virus Res. 2014; 89: 1-37.

[17] Su H, van Eerde A, Rimstad E, et al. Plant-made vaccines against viral diseases in humans and farm animals. Front Plant Sci. 2023; 14: 1170815.

[18] Kapusta J, Modelska A, Figlerowicz M, et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 1999; 13: 1796-1799.

[19] Govea-Alonso DO, Rybicki E, Rosales-Mendoza S. Plant-Based Vaccines as a Global Vaccination Approach: Current Perspectives. Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases. Springer Press; 2014: 265-280.

[20] Brüssow H. COVID-19: vaccination problems. Environ Microbiol. 2021; 23: 2878-2890.

[21] Chirico F, da Silva JAT, Tsigaris P, Sharun K. Safety & effectiveness of COVID-19 vaccines: a narrative review. Indian J Med Res. 2022; 155: 91-104.

[22] Matz KM, Marzi A, Feldmann H. Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev Vaccines. 2019; 18: 1229-1242.

[23] Mintaev RR, Glazkova DV, Orlova OV, et al. Development of MVA-d34 tetravalent dengue vaccine: design and immunogenicity. Vaccines. 2023; 11: 831.

[24] Bekker L-G, Tatoud R, Dabis F, et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020; 395: 384-388.

[25] Khoshnood S, Arshadi M, Akrami S, et al. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. J Clin Lab Anal. 2022; 36: e24418.

[26] Heaton PM. The Covid-19 vaccine-development multiverse. N Engl J Med. 2020; 383: 1986-1988.

[27] Thiel N, Selwyn C, Murphy G, Simpson S, Chakrabarti AC. Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine. NPJ Vaccines. 2021; 6: 63.

[28] Husain S, Nandi A, Simnani FZ, et al. Emerging trends in advanced translational applications of silver nanoparticles: a progressing dawn of nanotechnology. J Funct Biomater. 2023; 14: 47.

[29] Zarreen Simnani F, Singh D, Patel P, et al. Nanocarrier vaccine therapeutics for global infectious and chronic diseases. Mater Today. 2023; 66: 371-408.

[30] Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007; 449: 819-826.

[31] Zhai S, Kong MG, Xia Y. Cold atmospheric plasma ameliorates skin diseases involving reactive oxygen/nitrogen species-mediated functions. Front Immunol. 2022; 13: 868386.

[32] Kaner J, Schaack S. Understanding Ebola: the 2014 epidemic. Global Health. 2016; 12: 53.

[33] Li H, Liu S-M, Yu X-H. Tang S-L, Tang C-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicro Ag. 2020; 55: 105951.

[34] Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S. Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2022; 613: 130-137.

[35] Frierson JG. The yellow fever vaccine: a history. Yale J Biol Med. 2010; 83: 77-85.

[36] Taubenberger JK. The origin and virulence of the 1918 “Spanish” influenza virus. Proc Am Philos Soc. 2006; 150: 86-112.

[37] Schell KR. Vaccination against virus diseases. Sozial-und Praventivmedizin. 1979; 24: 335-345.

[38] Prieto-Martínez FD, López-López E, Juárez-Mercado KE, Medina-Franco JL. Computational drug design methods—current and future perspectives. In: In Silico Drug Design. 2019: 463-526.

[39] Hongzhuan Z, Ying T, Xia S, et al. Preparation of the inactivated Newcastle disease vaccine by plasma activated water and evaluation of its protection efficacy. Appl Microbiol Biotechnol. 2019; 104: 107-117.

[40] Mohamed H, Berman R, Connors J, et al. Immunomodulatory effects of non-thermal plasma in a model for latent HIV-1 infection: implications for an HIV-1-specific immunotherapy. Biomedicines. 2023; 11: 122.

[41] Kaushik NK, Bhartiya P, Kaushik N, et al. Nitric-oxide enriched plasma-activated water inactivates 229E coronavirus and alters antiviral response genes in human lung host cells. Bioact Mater. 2023; 19: 569-580.

[42] Choi M-S, Jeon EB, Kim JY, et al. Virucidal effects of dielectric barrier discharge plasma on human norovirus infectivity in fresh oysters (Crassostrea gigas). Foods. 2020; 9: 1731.

[43] Mohammadi MA, Ahangari H, Khajavi MZ, Yousefi M, Scholtz V, Hosseini SM. Inactivation of viruses using nonthermal plasma in viral suspensions and foodstuff: a short review of recent studies. J Food Saf. 2021; 41: e12919.

[44] Kaushik N, Mitra S, Baek EJ, et al. The inactivation and destruction of viruses by reactive oxygen species generated through physical and cold atmospheric plasma techniques: current status and perspectives. J Adv Res. 2023; 43: 59-71.

[45] Davies MJ. Protein oxidation and peroxidation. Biochem J. 2016; 473: 805-825.

[46] Guo L, Xu R, Gou L, et al. Mechanism of virus inactivation by cold atmospheric-pressure plasma and plasma-activated water. Appl Environ Microbiol. 2018; 84: e00726-18.

[47] Thapa B, Munk BH, Burrows CJ, Schlegel HB. Computational study of oxidation of guanine by singlet oxygen (¹Δ_g) and formation of guanine: lysine cross-links. Chem-Eur J. 2017; 23: 5804-5813.

[48] Bhartiya P, Lim JS, Kaushik N, et al. Nonthermal plasma-generated ozone inhibits human coronavirus 229E infectivity on glass surface. Plasma Process Polym. 2022; 19: e2200054.

[49] Mohamed H, Nayak G, Rendine N, et al. Non-thermal plasma as a novel strategy for treating or preventing viral infection and associated disease. Front Phys. 2021; 9: 683118.

[50] Micoli F, Bagnoli F, Rappuoli R, Serruto D. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol. 2021; 19: 287-302.

[51] Klingström J, Åkerström S, Hardestam J, et al. Nitric oxide and peroxynitrite have different antiviral effects against hantavirus replication and free mature virions. Eur J Immunol. 2006; 36: 2649-2657.

[52] Amanna IJ, Raué HP, Slifka MK. Development of a new hydrogen peroxide–based vaccine platform. Nat Med. 2012; 18: 974-979.

[53] Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271: C1424-C1437.

[54] Ischiropoulos H, al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett. 1995; 364: 279-282.

[55] Birnboim HC, Lemay A-M, Lam DKY, Goldstein R, Webb JR. Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. J Immunol. 2003; 171: 528-532.

[56] Rotem S, Bar-Haim E. Elia U, et al. A novel approach to vaccine development: concomitant pathogen inactivation and host immune stimulation by peroxynitrite. Vaccines. 2022; 10: 1593.

[57] Rabea S, Salem-Bekhit MM. Alanazi FK, Yassin AS, Moneib NA, Hashem AEM. A novel protocol for bacterial ghosts’ preparation using tween 80. Saudi Pharm J. 2018; 26: 232-237.

[58] Amara AA, Salem-Bekhit MM. Alanazi FK. Sponge-like: a new protocol for preparing bacterial ghosts. Sci World J. 2013; 2013: 545741.

[59] Park H, Oh S, Vinod N, et al. Characterization of chemically-induced bacterial ghosts (BGs) using sodium hydroxide-induced vibrio parahaemolyticus ghosts (VPGs). Int J Mol Sci. 2016; 17: 1904.

[60] Wu X, Ju X, Du L, et al. Production of bacterial ghosts from gram-positive pathogenlisteria monocytogenes. Foodborne Pathog Dis. 2017; 14: 1-7.

[61] Adam E, Delbrassinne L, Bouillot C, et al. Probiotic Escherichia coli nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway. Eur J Immunol. 2010; 40: 1995-2005.

[62] Quevedo-Diaz MA, Song C, Xiong Y, et al. Involvement of TLR2 and TLR4 in cell responses to Rickettsia akari. J Leukoc Biol. 2010; 88: 675-685.

[63] Hajam IA, Dar PA, Won G, Lee JH. Bacterial ghosts as adjuvants: mechanisms and potential. Vet Res. 2017; 48: 37.

[64] Fan Y, Mu Y, Lu L, et al. Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids. Int Immunopharmacol. 2019; 69: 389-397.

[65] Chen H, Ji H, Kong X, et al. Bacterial ghosts-based vaccine and drug delivery systems. Pharmaceutics. 2021; 13: 1892.

[66] Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science. 2017; 355: 1147-1152.

[67] Bekeschus S, Clemen R. Plasma, cancer, immunity. J Phys D: Appl Phys. 2022; 55: 473003.

[68] Buonaguro L, Tagliamonte M. Selecting target antigens for cancer vaccine development. Vaccines. 2020; 8: 615.

[69] Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005; 23: 2379-2387.

[70] Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022; 15: 28.

[71] Mohamed H, Gebski E, Reyes R, et al. Differential effect of non-thermal plasma RONS on two human leukemic cell populations. Cancers. 2021; 13: 2437.

[72] Omran AV, Busco G, Ridou L, et al. Cold atmospheric single plasma jet for RONS delivery on large biological surfaces. Plasma Sources Sci Technol. 2020; 29: 105002.

[73] Dünnbier M, Schmidt-Bleker A. Winter J, et al. Ambient air particle transport into the effluent of a cold atmospheric-pressure argon plasma jet investigated by molecular beam mass spectrometry. J Phys D: Appl Phys. 2013; 46: 435203.

[74] Bekeschus S, Clemen R, Metelmann H-R. Potentiating anti-tumor immunity with physical plasma. Clin Plasma Med. 2018; 12: 17-22.

[75] Bekeschus S, Rödder K, Fregin B, et al. Toxicity and immunogenicity in murine melanoma following exposure to physical plasma-derived oxidants. Oxid Med Cell Longev. 2017; 2017: 4396467.

[76] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013; 31: 51-72.

[77] Azzariti A, Iacobazzi RM, Di Fonte R, et al. Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Sci Rep. 2019; 9: 4099.

[78] Negi M, Kaushik N, Nguyen LN, Choi EH, Kaushik NK. Argon gas plasma-treated physiological solutions stimulate immunogenic cell death and eradicates immunosuppressive CD47 protein in lung carcinoma. Free Radic Biol Med. 2023; 201: 26-40.

[79] Van Loenhout J, Flieswasser T, Boullosa LF, et al. Cold atmospheric plasma-treated PBS eliminates immunosuppressive pancreatic stellate cells and induces immunogenic cell death of pancreatic cancer cells. Cancers. 2019; 11: 1597.

[80] Troitskaya O, Golubitskaya E, Biryukov M, et al. Non-thermal plasma application in tumor-bearing mice induces increase of serum HMGB1. Int J Mol Sci. 2020; 21: 5128.

[81] Lin A, Truong B, Patel S, et al. Nanosecond-pulsed DBD plasma-generated reactive oxygen species trigger immunogenic cell death in A549 lung carcinoma cells through intracellular oxidative stress. Int J Mol Sci. 2017; 18: 966.

[82] Lin A, Gorbanev Y, De Backer J, et al. Non-thermal plasma as a unique delivery system of short-lived reactive oxygen and nitrogen species for immunogenic cell death in melanoma cells. Adv Sci. 2019; 6: 1802062.

[83] Lin AG, Xiang B, Merlino DJ, et al. Non-thermal plasma induces immunogenic cell deathin vivo in murine CT26 colorectal tumors. Oncoimmunology. 2018; 7: e1484978.

[84] Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005; 202: 1691-1701.

[85] Khalili M, Daniels L, Lin A, et al. Non-thermal plasma-induced immunogenic cell death in cancer. J Phys D: Appl Phys. 2019; 52: 423001.

[86] Živanić M, Espona-Noguera A. Lin A, Canal C. Current state of cold atmospheric plasma and cancer-immunity cycle: therapeutic relevance and overcoming clinical limitations using hydrogels. Adv Sci. 2023; 10: 2205803.

[87] Labay C, Hamouda I, Tampieri F, Ginebra M-P, Canal C. Production of reactive species in alginate hydrogels for cold atmospheric plasma-based therapies. Sci Rep. 2019; 9: 16160.

[88] Solé-Martí X, Vilella T, Labay C, Tampieri F, Ginebra M-P, Canal C. Thermosensitive hydrogels to deliver reactive species generated by cold atmospheric plasma: a case study with methylcellulose. Biomater Sci. 2022; 10: 3845-3855.

[89] Solé-Martí X, Labay C, Raymond Y, et al. Ceramic-hydrogel composite as carrier for cold-plasma reactive-species: safety and osteogenic capacity in vivo. Plasma Process Polym. 2022; 20: 2200155.

[90] Zhang H, Xu S, Zhang J, et al. Plasma-activated thermosensitive biogel as an exogenous ROS carrier for post-surgical treatment of cancer. Biomaterials. 2021; 276: 121057.

[91] Connolly RJ, Chapman T, Hoff AM, Kutzler MA, Jaroszeski MJ, Ugen KE. Non-contact helium-based plasma for delivery of DNA vaccines. Hum Vaccin Immunother. 2012; 8: 1729-1733.

[92] Olinger GG, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 2012; 109: 18030-18035.

[93] Hiatt A, Caffferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature. 1989; 342: 76-78.

[94] Saxena J, Rawat S. Edible vaccines. Adv in Biotechnol. 2013; 207-226.

[95] Takeyama N, Kiyono H, Yuki Y. Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccines. 2015; 3: 139-154.

[96] Topp E, Irwin R, McAllister T, et al. The case for plant-made veterinary immunotherapeutics. Biotechnol Adv. 2016; 34: 597-604.

[97] Streatfield SJ, Howard JA. Plant-based vaccines. Int J Parasitol. 2003; 33: 479-493.

[98] Kumar AU, Kadiresen K, Gan WC, Ling APK. Current updates and research on plant-based vaccines for coronavirus disease 2019. Clin Exp Vaccine Res. 2021; 10: 13-23.

[99] Leuzinger K, Dent M, Hurtado J, et al. Efficient agroinfiltration of plants for high-level transient expression of recombinant proteins. J Visualized Exp. 2013; 77: 50521.

[100] Landry N, Ward BJ, Trépanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010; 5: e15559.

[101] Venkataraman S, Hefferon K, Makhzoum A, Abouhaidar M. Combating human viral diseases: will plant-based vaccines be the answer? Vaccines. 2021; 9: 761.

[102] Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med. 1998; 4: 607-609.

[103] Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine. 2004; 22: 4385-4389.

[104] Nochi T, Yuki Y, Katakai Y, et al. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity. J Immunol. 2009; 183: 6538-6544.

[105] Thanavala Y, Mahoney M, Pal S, et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci USA. 2005; 102: 3378-3382.

[106] D’Aoust MA, Lavoie PO, Couture MM, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamianainduce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J. 2008; 6: 930-940.

[107] Cummings JF, Guerrero ML, Moon JE, et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A(H1N1)pdm09 virus: a phase 1 dose-escalation study in healthy adults. Vaccine. 2014; 32: 2251-2259.

[108] Tregoning JS. First human efficacy study of a plant-derived influenza vaccine. Lancet. 2020; 396: 1464-1465.

[109] Kessans SA, Linhart MD, Meador LR, et al. Immunological characterization of plant-based HIV-1 gag/Dgp41 virus-like particles. PLoS One. 2016; 11: e0151842.

[110] Meyers A, Chakauya E, Shephard E, et al. Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol. 2008; 8: 53.

[111] Pérez-Filgueira DM, Brayfield BP, Phiri S, Borca MV, Wood C, Morris TJ. Preserved antigenicity of HIV-1 p24 produced and purified in high yields from plants inoculated with a tobacco mosaic virus (TMV)-derived vector. J Virol Methods. 2004; 121: 201-208.

[112] Orellana-Escobedo L, Rosales-Mendoza S. Romero-Maldonado A, et al. An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice. Plant Cell Rep. 2014; 34: 425-433.

[113] Matoba N, Kajiura H, Cherni I, et al. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Plant Biotechnol J. 2009; 7: 129-145.

[114] Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis. 2000; 182: 302-305.

[115] Yusibov V, Hooper DC, Spitsin SV, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine. 2002; 20: 3155-3164.

[116] Zheng N, Xia R, Yang C, et al. Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice. Vaccine. 2009; 27: 5001-5007.

[117] Pogrebnyak N, Golovkin M, Andrianov V, et al. Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine. Proc Natl Acad Sci U S A. 2005; 102: 9062-9067.

[118] Mamedov T, Yuksel D, Ilgın M, et al. Production and characterization of nucleocapsid and RBD cocktail antigens of SARS-CoV-2 in Nicotiana benthamiana plant as a vaccine candidate against COVID-19. Vaccines. 2021; 9: 1337.

[119] Maharjan PM, Choe S. Plant-based COVID-19 vaccines: current status, design, and development strategies of candidate vaccines. Vaccines. 2021; 9: 992.

[120] Gobeil P, Pillet S, Boulay I, et al. Phase 2 randomized trial of an AS03 adjuvanted plant-based virus-like particle vaccine for Covid-19 in healthy adults, older adults and adults with comorbidities. medRxiv. 2021: 5.

[121] Hager KJ, Marc GP, Gobeil P, et al. Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine. N Engl J Med. 2022; 386: 2084-2096.

[122] Márquez-Escobar VA, Rosales-Mendoza S. Beltrán-López JI, González-Ortega O. Plant-based vaccines against respiratory diseases: current status and future prospects. Expert Rev Vaccines. 2016; 16: 137-149.

[123] Dhama K, Natesan S, Iqbal Yatoo M, et al. Plant-based vaccines and antibodies to combat COVID-19: current status and prospects. Hum Vaccin Immunother. 2020; 16: 2913-2920.

RIGHTS & PERMISSIONS

2024 The Authors. SmartMat published by Tianjin University and John Wiley & Sons Australia, Ltd.